Akums Drugs and Pharmaceuticals Limited — Investor Meet, 08-08-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Akums Drugs reported Q1 FY26 financial results: Total income of ₹1,051 Cr (+2.4% YoY), Adjusted EBITDA at ₹156 Cr (14.8% margin, +208 bps YoY), and Adjusted PAT at ₹65 Cr (6.2% margin, +57 bps YoY). The company reached 1,000 DCGI approvals and secured its first EU dossier approval. A €100 million advance for a European CDMO contract boosted cash surplus to ₹1,518 Cr. Management remains focused on strengthening CDMO leadership and driving operational excellence for sustainable growth, despite muted market volumes and weak API prices. Outlook for long-term growth is positive.